This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Astrazeneca Ab. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Robert Evans Ziegler: Innovator in Cancer Treatment
Introduction
Robert Evans Ziegler is an inventor based in Gaithersburg, MD (US). He is focused on developing innovative solutions for cancer treatment. Although he currently holds no granted patents, his work in the field of pharmaceuticals is noteworthy.
Latest Patent Applications
Ziegler's latest patent applications include "SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER." This application discloses certain substituted pyrazine-2-carboxamides of Formula (I), along with their pharmaceutically acceptable salts. These compounds serve as inhibitors of hematopoietic progenitor kinase 1 (HPK1) and are particularly useful in the treatment or prophylaxis of cancer. Another application is titled "HETEROAROMATIC COMPOUNDS," which relates to compounds of Formula (1) and their pharmaceutically acceptable salts. This application also discusses processes and intermediates used for their preparation, as well as pharmaceutical compositions containing them and their use in cancer treatment.
Conclusion
Robert Evans Ziegler is making significant strides in the field of cancer treatment through his innovative patent applications. His focus on developing effective therapies highlights the importance of research and innovation in combating serious health challenges.